Main Business / Finance News Today
GOLDMAN SACHS ALERT: Bragar Eagel & Squire, P.C. is Investigating The Goldman...
Share buybacks in Spar Nord Bank transactions in week 03
MUNIC EKKO platform & OBD Dongles power Smart Connect project from ADAC...
OPENING OF 2.25 PER CENT BULLET LOAN 2033
Product Leaders Podcast Features Fireart Leaders as their Lead Hosts
Municipality Finance issues EUR 10 million notes under its MTN programme
2023-01-24 10:06:59

Alvotech, Bioventure Announce Approval For Humira Biosimilar Simlandi In Saudi

Logo Nasdaq
Nasdaq
By Rtt News

(RTTNews) - Alvotech (ALVO) and Bioventure Tuesday announced manufacturing and distribution approval of AVT02, a biosimilar of Humira, by the Saudi Food and Drug Authority or SFDA. The drug was found to be more affordable and with no clinically meaningful differences. The biosimilar will be marketed as Simlandi in Saudi.

Humira is indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases. Bioventure is a subsidiary of GlobalOne Healthcare Holding LLC of Yas Holding LLC

GlobalOne Healthcare said, "We look forward to bringing this essential treatment to patients in Saudi Arabia as well as other key markets in the Middle East and North Africa."

Continue read on nasdaq.com

Related Posts
Logo GlobeNewswire
SciencePress Release2023-01-24 09:00:00
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
AVT02 as Simlandi is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure REYKJAVIK, Iceland and DUBAI, United Arab...
Logo EIN Presswire
HealthPress Release2023-01-23 13:38:17
Personalized Therapy Biosimulation Market Size Worth $3,164.1 Mn and Growing at a CAGR of 14.6% by 2028
Emergen Research Logo Increasing number of drug relapse and drug resistance cases and application of QSP in drug development processes are some key factors...
Logo GlobeNewswire
SciencePress Release2023-01-24 06:00:00
Hyloris Announces Commercial Partnership for Maxigesic IV in 9 European Countries
Exclusive licensing and distribution agreement signed with Salus Pharmaceuticals in Lithuania, Estonia, Latvia, Croatia, Slovenia, Serbia, North Macedonia,...
Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 10:00:00
ATUM Announces Leap-In Transposase Licensing Agreement with Codiak Biosciences to Support Manufacturing
ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In...
Logo Nasdaq
Business / FinanceBy Rtt News2023-01-23 13:22:13
Blueprint Medicines: FDA Grants Priority Review For Supplemental New Drug Application For AYVAKIT
(RTTNews) - Blueprint Medicines Corporation (BPMC) announced the FDA has accepted the company's supplemental new drug application for AYVAKIT for the...
Logo PR Newswire
Business / FinancePress Release2023-01-23 19:46:00
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at...
Logo Benzinga
Business / FinanceBy Business Wire2023-01-23 12:45:00
KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
Following the recent Sudan ebolavirus outbreak in Uganda, KBI is providing emergency support through global production efforts KBI Biopharma, Inc. (KBI), a...
Logo GlobeNewswire
SciencePress Release2023-01-23 14:22:00
Bioasis Technologies Inc. Announces Termination ofArrangement Agreement with Midatech Pharma plc
NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the Company or Bioasis ), a multi-asset rare and...
Logo PR Newswire
HealthPress Release2023-01-23 13:00:00
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the...
-- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE, Mass., Jan. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation...
Logo PR Newswire
HealthPress Release2023-01-23 14:05:00
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
LEXINGTON, Mass., Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Logo EIN Presswire
Business / FinancePress Release2023-01-23 13:19:44
Biostimulants Market Business Opportunities, Survey, Growth Analysis And Industry Outlook
Emergen Research Logo Limited entry barriers resulting in the entry of players of different tiers is a key factor driving biostimulants market revenue growth...
Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-23 11:00:00
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance
- Initiated Phase 2 clinical trial evaluating Darovasertib as neoadjuvant treatment of uveal melanoma prior to primary interventional treatment of...
Logo PR Newswire
HealthPress Release2023-01-23 14:00:00
Orlando Health Selects Biofourmis to Enable Optimal Hospital-Level Care in Patients' Homes
Multi-year agreement to launch in early 2023 Biofourmis selected due to industry-leading technological capabilities as well as breadth of operational,...
Logo GlobeNewswire
SciencePress Release2023-01-23 12:00:00
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO (berotralstat) in Central and Eastern Europe
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the company has entered into a...
Logo EIN Presswire
HealthPress Release2023-01-23 14:28:26
U.S. Human Microbiome Modulators Market : A Breakdown of the Industry by Technology, Application, and Geography
Emergen Research Logo Increasing investments in healthcare infrastructure is the key factor driving market revenue growth U.S. Human Microbiome Modulators...
Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-23 23:55:27
Carina Biotech Receives FDA Safe to Proceed Letter for IND Application for Phase 1/2a Clinical Trial of
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103 On track to commence patient enrollment during the first half 2023 ADELAIDE,...
Logo NewsFileCorp
Press Release2023-01-23 14:37:00
Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs
Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to...
Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-23 23:30:00
Sandoz announces agreement to acquire leading antifungal agent Mycamine from Astellas, reinforcing hospi
Basel, January 24, 2023 Sandoz, the global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product...
Logo GlobeNewswire
SciencePress Release2023-01-23 12:00:00
Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ET BEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Matinas...
Logo GlobeNewswire
SciencePress Release2023-01-23 23:55:00
Carina Biotech Receives FDA Safe to Proceed Letter for IND Application for Phase 1/2a Clinical Trial of LGR5-Targeted...
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103 On track to commence patient enrollment during the first half 2023 ADELAIDE,...